Postoperative gastrointestinal symptoms are common in patients undergoing sleeve gastrectomy. This study is aimed to assess the effectiveness of omentopexy during laparoscopic sleeve gastrectomy in reducing gastrointestinal symptoms.
A retrospective analysis of patients who underwent laparoscopic sleeve gastrectomy with and without omentopexy in the period between January 2016 to September 2017. All procedures were performed by three surgeons utilizing the same surgical technique. Data extracted included patient socio-demographics’, preoperative body mass index (BMI), hospitalization period, treatments and post-operative gastrointestinal symptoms. It also contained the GERD-Health Related Quality of Life Questionnaire (GERD-HRQL) measuring symptom severity in gastroesophageal reflux disease (GERD). Data were analysed at 6, 12 and 18 months with reference to weight loss.
A total of 140 patients were included in this study, 70 in each group arm, and were followed up for more than a year. Age, gender, preoperative BMI, pre-operative co-morbid conditions like hypertension, diabetes, and asthma were considered as confounding variables among the two groups. None of the previous factors were statistically significantly different among both groups. The outcomes of both groups were compared in terms of postoperative nausea, vomiting, regurgitation, intra-hospital stay, medication use, early return to work, and EWL%. None of the previous outcomes was found to be significantly different between both groups.
Omentopexy does not change the outcome for laparoscopic sleeve gastrectomy in terms of gastrointestinal symptoms or weight loss results.